Reported Wednesday, HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608M To Focus On Core R&D And Innovative Oncology Therapies
Reported Wednesday, HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608M To Focus On Core R&D And Innovative Oncology Therapies
报道称，HUTCHMED将其在上海和记辉瑞的45%股份出售，金额为60800万美元，以便专注于核心研发和创新肿瘤治疗。
- HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —
- Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business —
- Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 —
- HUTCHMED继续执行其在2022年11月制定的策略，以创造价值，优先考虑其产品组合，并将创新药物带给全球患者——
- 剥离收益将用于推进HUTCHMED的研发管线和核心创新药物业务——
- 聚焦的研发投资包括HUTCHMED自有的抗体靶向治疗偶联平台，首批候选药物预计将在2025年下半年进入临床试验——
资讯热榜
更新时间